Phase I Trial of Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Fully Human Monoclonal Antibody to RANKL (TK006) in Post-menopausal Women.
Phase of Trial: Phase I
Latest Information Update: 16 Mar 2018
At a glance
- Drugs Denosumab (Primary)
- Indications Postmenopausal osteoporosis
- Focus Adverse reactions
- Sponsors Jiangsu T-mab BioPharma
- 31 Aug 2018 Biomarkers information updated
- 13 Mar 2018 Status changed from not yet recruiting to recruiting.
- 21 Aug 2017 Planned initiation date changed from 12 Aug 2017 to 1 Sep 2017.